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1. INTRODUCTION {#cam43197-sec-0005}
===============

Prostate Cancer (PC) remains the most frequently diagnosed cancer in men in many Western countries with an age‐adjusted cumulative incidence rate in Switzerland of 129.6/100,000.[^1^](#cam43197-bib-0001){ref-type="ref"} Over the last decades, PC prognosis has substantially improved resulting in a 5‐year relative survival rate of 90% in Switzerland.[^2^](#cam43197-bib-0002){ref-type="ref"} Although radical prostatectomy (RP) is the most common treatment strategy for men diagnosed with PC [^3^](#cam43197-bib-0003){ref-type="ref"} with 88.2 RP/100'000 men in Switzerland,[^1^](#cam43197-bib-0001){ref-type="ref"} the survival benefit for PC survivors treated with RP compared to other primary management options remains unclear.[^4^](#cam43197-bib-0004){ref-type="ref"}, [^5^](#cam43197-bib-0005){ref-type="ref"}, [^6^](#cam43197-bib-0006){ref-type="ref"} For example, an analysis of PC survivors in the Swiss canton of Zurich revealed similar relative 1‐, 5‐, and 10‐year survival rates for PC survivors treated either with RP or radiotherapy.[^7^](#cam43197-bib-0007){ref-type="ref"} In addition, RP may have both strong acute and long‐lasting detrimental effects, notably on urinary and sexual functioning.[^8^](#cam43197-bib-0008){ref-type="ref"}, [^9^](#cam43197-bib-0009){ref-type="ref"}, [^10^](#cam43197-bib-0010){ref-type="ref"}, [^11^](#cam43197-bib-0011){ref-type="ref"}

Nerve‐sparing (NS) technique was developed to improve postoperative sexual function (SEF) [^12^](#cam43197-bib-0012){ref-type="ref"} and potentially urinary outcomes after RP. Indeed, higher recovery rates of SEF after nerve‐sparing RP compared to non‐nerve‐sparing (Non‐NS) RP could be observed up to 24 months.[^13^](#cam43197-bib-0013){ref-type="ref"}, [^14^](#cam43197-bib-0014){ref-type="ref"} However, a positive effect for postoperative urinary outcomes remains controversial.[^15^](#cam43197-bib-0015){ref-type="ref"}, [^16^](#cam43197-bib-0016){ref-type="ref"} For example, a study performed at the cantonal hospital Graubünden among 453 PC patients treated with robot‐assisted RP, whereas 265 patients (58.5%) were operated nerve‐sparing, showed that planed nerve‐sparing was not associated with an improved continence rate.[^17^](#cam43197-bib-0017){ref-type="ref"} A systematic review published in 2015 concluded that preservation of the neurovascular bundles improves urinary continence in the first 6 months after surgery, but no effect was seen for later time points up to 5 years after treatment.[^18^](#cam43197-bib-0018){ref-type="ref"}

Even though extensive research was performed regarding whether NSRP improves urinary outcomes and SEF compared to Non‐NSRP in the first time 6‐24 months after the operation, little attention has been given to long‐term effects. Also research regarding whether NSRP compared to Non‐NSRP affects general health‐related quality of life (HRQoL) remains limited. To the authors' knowledge, only one study from the United States [^19^](#cam43197-bib-0019){ref-type="ref"} has assessed HRQoL domains (physical functioning and mental health) and disease‐specific symptom burden in PC survivors up to 10 years after diagnosis either treated with NSRP or Non‐NSRP. In this longitudinal study, PC survivors treated with Non‐NSRP reported similar declines at 5 years after diagnosis in physical functioning, mental health, and urinary continence scores compared to survivors treated with NSRP but significantly stronger declines in SEF scores. However, no study assessed further HRQoL functions and cancer and treatment‐related symptom burden beside urinary outcomes and SEF in long‐term PC survivors. Therefore, the objective of our study was to identify differences and similarities in general HRQoL and PC‐specific symptom burden by NSRP (uni/bilateral) and Non‐NSRP in long‐term PC survivors.

2. MATERIAL AND METHODS {#cam43197-sec-0006}
=======================

2.1. Study design and study population {#cam43197-sec-0007}
--------------------------------------

Participants were included from the multiregional *Prostate Cancer Survivorship in Switzerland* (PROCAS) cohort. Details of the PROCAS study recruitment and data collection design have been described elsewhere.[^20^](#cam43197-bib-0020){ref-type="ref"} In short, the PROCAS study included 748 long‐term PC survivors who were diagnosed between 2006 and 2011 and aged 42‐75 years at diagnosis. They were identified via six population‐based cancer registries (Cancer Registry Fribourg, Cancer Registry Basel, Cancer Registry Graubünden and Glarus, Cancer Registry East Switzerland, Valais Cancer Registry & Cancer Registry Zurich and Zug) covering an underlying population of 3 456 020 million inhabitants, based in both German and French‐speaking Switzerland and invited via their referring urologists. Data collection was conducted between 2017 and 2018 by postal questionnaire. Nonrespondents received one reminder. Among PC survivors, 8712 fulfilled the inclusion criteria for the study (Figure [1](#cam43197-fig-0001){ref-type="fig"}). Of them, 1246 PC survivors were randomly selected for participation. 1194 could be contacted and received an invitation. Finally, 748 returned a completed questionnaire (response rate: 62.2%). This analysis was restricted to PC survivors (a) staged pT2‐T3 N0 and M0 (according to the TNM classification system published by the American Joint Committee on Cancer have been available in the FCD since 2002[^21^](#cam43197-bib-0021){ref-type="ref"}), (b) treated with RP as primary therapy, and (c) recruited from cancer registries (Cancer Registry Graubünden and Glarus, Cancer Registry East Switzerland, Valais Cancer Registry & Cancer Registry Zurich and Zug), which provided information on degree of NSRP (N = 382). Our sample was restricted to pT2‐T3N0M0 cases to create a homogenous cohort, because PC patients staged pT4 or with cancer in lymph nodes or metastases need different treatment strategies.

![Study Flowchart. \*For PC survivors in the cantons of Basel‐Stadt (BS), Basel‐Landschaft (BL), and Fribourg (FR) information on degree of NSRP was not available](CAM4-9-5416-g001){#cam43197-fig-0001}

3. STUDY MEASURES {#cam43197-sec-0008}
=================

3.1. HRQoL and PC‐specific symptom burden {#cam43197-sec-0009}
-----------------------------------------

HRQoL and PC‐specific symptom burden were assessed once (cross‐sectional design) with internationally validated instruments: the EORTC QLQ‐C30 and the PC‐specific module QLQ‐PR25. The EORTC QLQ‐C30 questionnaire consists of 30 items, comprising five functioning scales, a global health/quality of life (QoL) scale, and nine items/scales on symptoms and financial difficulties. The PC‐specific EORTC QLQ‐PR25 questionnaire consists of 25 questions, assessing urinary and bowel symptoms, sexual activity, sexual functioning, and hormonal treatment‐related symptoms. Scoring of all instruments was performed according to the pertinent scoring manuals.[^22^](#cam43197-bib-0022){ref-type="ref"}, [^23^](#cam43197-bib-0023){ref-type="ref"} High scores on the functioning scales and global health/QoL indicate better functioning and better health, respectively. For the symptom and financial difficulty scales, a higher score represents a greater symptom burden and financial difficulty. High scores in the EORTC QLQ‐PR25 represent a greater symptom burden or a better sexual functioning and more sexual activity.

3.2. Demographics, lifestyle, and clinical data {#cam43197-sec-0010}
-----------------------------------------------

Information whether patients were treated with NSRP and whether it was uni‐ or bilateral NSRP were provided by the treating urologist, together with the cantonal and regional cancer registries. Assessment whether NSRP was performed nerve‐sparing was based on the surgeons' appraisal. Physicians also gave detailed information on other treatments, disease progression/ relapse (including biochemical and clinical recurrence and metastasis after diagnosis of primary tumor at time of survey) and other primary tumors. Cancer registries provided demographic parameters and clinical information such as date of birth, date of diagnosis and cancer stage. Self‐reported demographic included education, living with partner, working status, weight, height, and nationality. Questionnaires and all other study documents were available in German, French, and Italian.

4. STATISTICS {#cam43197-sec-0011}
=============

For descriptive purposes, we compared Non‐NSRP (n = 167) vs NSRP (n = 215) by several clinical and sociodemographic characteristics. The group NSRP consisted of PC survivors treated with both uni‐ and bilateral NSRP, as these two groups did not differ with respect to clinical and sociodemographic characteristics (Table [S1](#cam43197-sup-0001){ref-type="supplementary-material"}) and reported similar HRQoL outcomes (Tables [S2](#cam43197-sup-0001){ref-type="supplementary-material"}). Additionally, we compared uni‐ and bilateral NSRP with Non‐NSRP separately in order to determine whether outcomes of unilateral NSRP and Non‐NSRP might be more similar to each another than they were to bilateral NSRP.

Adjusted means based on multivariable linear regression models were calculated to describe and test for differences in HRQoL. Models were adjusted for age at survey, years since diagnosis, cancer stage at diagnosis, comorbidities at diagnosis, and further therapy (during 1st year after diagnosis) if appropriate. Other variables including education, working status, nationality, and language were considered as additional potential confounders, but not included as they did not improve the model fit.

To assess the effect of age and disease progression/relapse, we performed sensitivity analysis: (a) excluding all patients with a disease progressions/relapse and (b) stratifying by age using the mean of 72.4 years as cut‐off.

Multiple Imputation Chained Equations (MICE) procedure with 25 repetitions was used to reduce possible bias due to missing values. MICE is the standard procedure in epidemiological research under the missing‐at‐random assumption.[^24^](#cam43197-bib-0024){ref-type="ref"} It has the advantage that missing values are filled multiple times "(...) based on the observed values for a given individual and the relation observed in the data for other participants (...)".[^25^](#cam43197-bib-0025){ref-type="ref"} Therefore, the analyses of the multiple imputed data consider the uncertainty in the imputed data, resulting in accurate standard errors.[^25^](#cam43197-bib-0025){ref-type="ref"} Differences in mean HRQoL scores larger than 10 points were considered clinically meaningful.[^26^](#cam43197-bib-0026){ref-type="ref"} A *P*‐value \< .05 (two‐sided) was considered statistically significant. The *P*‐values were not adjusted for multiple testing, so the *P*‐values refer to the individual tests rather than a global test for differences. All analyses were performed using STATA statistical software (Version 15.1).

5. RESULTS {#cam43197-sec-0012}
==========

Overall, from 382 PC survivors included in this analysis 56.3%, received NSRP and 43.7% Non‐NSRP (Table [1](#cam43197-tbl-0001){ref-type="table"}). Mean age was 72.4 years and mean time since diagnosis was 7.5 years. Participants had mainly Swiss nationality and filled‐in the German questionnaire. Beside years since diagnosis (*P* = .026) and disease progression (*P* = .029), clinical and demographic characteristics were comparable among PC survivors by treatment strategy. For PC survivors treated with Non‐NSRP mean time since diagnosis was 7.8 years, whereas it was 7.4 years for PC survivors treated with NSRP. Moreover, disease progression/relapse was more likely among participants on Non‐NSRP (28.8% vs 17.7%).

###### 

Demographic and clinical characteristics of PC survivors by nerve‐sparing status (after multiple imputation of missing values)

                                                                        Total        Non‐NSRP     NSRP         Non‐NSRP vs NSRP
  --------------------------------------------------------------------- ------------ ------------ ------------ ------------------
  Age at survey                                                                                                
  \<70 years                                                            30.4         29.6         31.7         
  70‐74 years                                                           32.2         31.1         33.0         
  75‐79 years                                                           25.1         25.0         25.2         
  ≥80 years                                                             12.3         15.2         10.1         
  Mean (SD)                                                             72.4 (6.3)   72.9 (6.5)   71.9 (6.3)   .236
  Education (highest degree)[^a^](#cam43197-note-0003){ref-type="fn"}                                          
  Low                                                                   0.8          0.6          0.9          
  Medium                                                                51.2         50.3         51.8         
  High                                                                  48.0         49.1         47.3         .572
  Nationality Swiss (yes)                                               95.5         96.0         95.2         .752
  Language questionnaire                                                                                       
  German                                                                94.8         97.0         93.0         
  French/Italian                                                        5.2          3.0          7.0          .127
  Living with partner (yes)                                             82.3         78.1         85.5         .197
  Working at survey (yes)                                               11.8         10.4         12.9         .54
  Body Mass Index                                                                                              
  \<18.5                                                                0.3          0.6          0.0          
  18.5‐24.9                                                             35.1         31.1         38.0         
  25.0‐29.9                                                             52.0         51.6         51.6         
  ≥30                                                                   12.6         16.8         10.4         .212
  Cancer stage                                                                                                 
  pT2N0M0                                                               77.4         72.8         82.0         
  pT3N0M0                                                               22.6         27.2         18.0         .087
  Years since diagnosis                                                                                        
  5‐6                                                                   27.2         22.3         31.0         
  7‐8                                                                   46.1         43.8         47.8         
  9‐10                                                                  26.7         33.9         21.1         
  Mean (SD)                                                             7.5 (1.4)    7.8 (1.5)    7.4 (1.5)    .026
  Disease progression/relapse (yes)                                     22.0         28.4         17.7         .029
  Comorbidities at diagnosis                                                                                   
  0                                                                     72.4         80.0         66.9         
  1                                                                     19.1         12.2         24.2         
  ≥2                                                                    8.5          7.8          8.9          .091
  Further therapy (during 1st year after diagnosis)                                                            
  External‐beam radiation therapy                                       6.6          7.8          5.6          .584
  Hormone therapy                                                       4.0          4.3          3.7          .850

Abbreviation: Col, Column.

Education: Low (no or primary school); Medium (lower general secondary education or vocational training); High (pre‐university education, high vocational training, university).

John Wiley & Sons, Ltd

Multiple imputation did not substantially alter the distribution of Non‐NSRP and NSRP (Table [S3](#cam43197-sup-0001){ref-type="supplementary-material"}) and their association with baseline clinical and demographic characteristics (Tables [S4](#cam43197-sup-0001){ref-type="supplementary-material"}) and HRQoL outcomes (Table [S5](#cam43197-sup-0001){ref-type="supplementary-material"}).

5.1. HRQoL and PC‐specific symptom burden of PC survivors treated with Non‐NSRP vs NSRP {#cam43197-sec-0013}
---------------------------------------------------------------------------------------

In general, PC survivors reported excellent functioning and good general health/overall quality of life. Adjusted mean scores of all functioning scales were comparable between PC survivors who have received Non‐NSRP and NSRP (Figure [2](#cam43197-fig-0002){ref-type="fig"}, all *P*‐values \> .05).

![Adjusted mean scores of EORTC QLQ‐C30 HRQoL scales of PC survivors by nerve‐sparing status (after multiple imputation of missing values). A high score represents a high/healthy level of functioning/high QoL. Mean scores were adjusted for age at survey, years since diagnosis, cancer stage, comorbidities at diagnosis, and further therapy if appropriate. I bars represent ± standard errors; all *P*‐values \> .05](CAM4-9-5416-g002){#cam43197-fig-0002}

Fatigue, insomnia and pain were the symptoms with the highest reported burden among all PC survivors. However, differences in adjusted mean scores between patients treated with Non‐NSRP and NSRP were small (max. 2.8 scale points) and not statistically significant (Figure [3](#cam43197-fig-0003){ref-type="fig"}, all *P*‐values \> .05).

![Adjusted mean of EORTC QLQ‐C30 symptom scales of PC survivors by nerve‐sparing status (after multiple imputation of missing values). A high score represents a high symptom burden. Mean scores were adjusted for age at survey, years since diagnosis, cancer stage, comorbidities at diagnosis, and further therapy if appropriate. I bars represent ± standard errors; all *P*‐values \> .05](CAM4-9-5416-g003){#cam43197-fig-0003}

PC survivors who underwent NSRP reported statistically significant (*P* = .031) higher sexual activity (not clinically significant different), but similar sexual functioning compared to those who have received Non‐NSRP (Figure [4](#cam43197-fig-0004){ref-type="fig"}). Regarding urinary symptoms and urinary bother no significant different mean scores were reported.

![Adjusted mean of EORTC PR25 scales of PC survivors by nerve‐sparing status (after multiple imputation of missing values).A high score represents higher symptom burden or higher sexual activity/ better sexual functioning. Mean scores were adjusted for age at survey, years since diagnosis, cancer stage, comorbidities at diagnosis and further therapy if appropriate.^1^ smaller sample size as questions regarding these functions were conditional---urinary bother (n = 104) & sexual functioning (n = 183)I bars represent ± standard errors; all *P*‐values \> .05 if not indicated otherwise](CAM4-9-5416-g004){#cam43197-fig-0004}

Neither differences in urinary symptoms (n = 132), urinary bother (n = 37) nor sexual activity (n = 131) and sexual function (n = 73) were observed when comparing HRQoL and PC‐specific symptom burden of PC survivors treated with unilateral NSRP vs bilateral NSRP (Table [S2](#cam43197-sup-0001){ref-type="supplementary-material"}). When unilateral and bilateral NSRP were compared to Non‐NSRP separately, results showed a similar pattern, indicating that unilateral NSRP outcomes were not more similar to Non‐NSRP than to bilateral NSRP (data not shown).

Restriction to long‐term PC survivors without disease progression/relapse did not substantially alter the pattern of our findings (data not shown). Furthermore, the pattern of our findings was similar in age‐stratified analyses. However, younger long‐term survivors (\<72.4 years of age) reported higher HRQoL functioning scores and lower symptom burden scores (Table [S6](#cam43197-sup-0001){ref-type="supplementary-material"} & Table [S7](#cam43197-sup-0001){ref-type="supplementary-material"}). Even though younger long‐term PC survivors treated with NSRP reported a 6.3‐point higher score for sexual activity, this difference was statistically significant (*P* = .043) and clinically meaningful only in older long‐term PC survivors.

6. DISCUSSION {#cam43197-sec-0014}
=============

Given the increasing numbers of long‐term PC survivors,[^27^](#cam43197-bib-0027){ref-type="ref"} it is imperative to understand whether treatment modalities such as NSRP may result in long‐lasting health benefits including better HRQoL and lower PC‐specific symptom burden. This population‐based study suggests, however, that HRQoL and symptom burden in PC survivors 5‐10 years after diagnosis of localized PC in general does not vary according to type of surgery (NSRP versus Non‐NSRP) except for the finding that PC survivors who underwent NSRP were significantly more sexually active than those treated with Non‐NSRP.

In general, the results from our cross‐sectional survey confirm and extend the results of the longitudinal survey based on the CaPSURE registry.[^19^](#cam43197-bib-0019){ref-type="ref"} In addition to the results from the CaPSURE registry which described differences in SEF but comparable physical and mental health in PC survivors after NSRP and Non‐NSRP, there appears to be no further differences between the two treatment groups with respect to global health status, role, emotional, cognitive, and social functioning as well as burden of fatigue, insomnia, dyspnoea, constipation and pain according to our study. The result that no differences were observed in any non‐PC‐specific HRQoL and symptom burden domains is in line with previous studies, which reported little to no difference in HRQoL of long‐term PC survivors between treatment modalities [^9^](#cam43197-bib-0009){ref-type="ref"} or in comparison with the general population.[^11^](#cam43197-bib-0011){ref-type="ref"} An explanation for this finding might be the response shift phenomenon, which results in a change in perception of burden threshold[^28^](#cam43197-bib-0028){ref-type="ref"}, [^29^](#cam43197-bib-0029){ref-type="ref"} after a cancer diagnosis. Even though long‐term PC survivors treated with Non‐NSRP suffer from worse SEF than survivors treated with NSRP, there is no impact on other HRQoL domains.

Previous studies have reported that NSRP improves postoperative sexual function up to five[^13^](#cam43197-bib-0013){ref-type="ref"}, [^14^](#cam43197-bib-0014){ref-type="ref"}, [^30^](#cam43197-bib-0030){ref-type="ref"} and 10 years after diagnosis[^19^](#cam43197-bib-0019){ref-type="ref"} compared to Non‐NSRP. In our study, no significant differences for SEF were reported, but patients treated with NSRP scored significantly higher on all sexual activity scales. The discrepancy between our results and the aforementioned studies is potentially based on the usage of different instruments to assess PC‐specific symptom burden. In this study, the EORTC‐PR25 questionnaire was used, whereas the other studies used the UCLA‐PCI and the EPIC‐26 questionnaire. In the EORTC‐PR25, sexual activity is measured with two questions, which are asking about sexual interest and frequency of sexual activity. Only patients who were sexually active (183/382) answered the additional questions on the ability to have an erection and orgasm, and sexual desire,[^23^](#cam43197-bib-0023){ref-type="ref"} which corresponds to the SEF domain. In contrast, all these items including level of sexual activity are part of the SEF domain in the other two instruments.[^31^](#cam43197-bib-0031){ref-type="ref"} Therefore, results regarding SEF from studies using different QoL instruments are not directly comparable. Nevertheless, our finding that NSRP results in favourable sexual function even 5‐10 years after diagnosis has potential clinical implications, even though the difference was small (not clinically meaningful), indicating that the impact may be less important for the individual. However, as the number of long‐term PC survivors is substantially growing,[^32^](#cam43197-bib-0032){ref-type="ref"} a large number of individuals are affected. Moreover, most PC survivors have very good survival perspectives and live with their partners. Therefore, we believe that our results might have an impact on the treatment decision‐making process.

In this context, the focus should be on older long‐term PC survivors. Even though, as indicated in an analysis of long‐term PC survivors in Germany,[^11^](#cam43197-bib-0011){ref-type="ref"} HRQoL scores are probably lower and symptom burden scores higher in older long‐term PC survivors; the differences in sexual activity in older PC survivors were not only statistically significant but also larger (clinically meaningful) than in younger survivors. Thus, the chances to preserve sexual activity should also play a role in elderly patient groups when deciding for a treatment strategy. However, these results need to be interpreted with caution due to the small sample size.

The lack of differences with respect to long‐term urinary symptoms and urinary bother might be surprising, but our results are similar to another study performed in Switzerland,[^16^](#cam43197-bib-0016){ref-type="ref"} even though studies differ methodologically. The latter study continuously assessed and compared urinary incontinence over a 10‐year period in PC survivors either treated with NSRP or Non‐NSRP. This study was conducted in a canton, which was not part of this study, and adjusted its models for factors (such as PC volume, clinical risk group, positive margins, and preoperative urinary incontinence score and PSA‐values), which were not assessed in our study. Beside those differences, the similarity of the results supports the conclusion of the other study, stating that NSRP should not be conducted with the primary aim to improve urinary outcomes.

To our knowledge, this is the first study performed in Europe which compared HRQoL and PC‐specific symptom burden according to NS surgery in long‐term PC survivors, using a multiregional‐based design, including patient recruitment via multiple population‐based cancer registries in two different language regions. Beside these strengths, there are limitations which need to be discussed. For example, not in all study regions, information was available whether participants received NSRP. Therefore, participants of two study regions were excluded from this analysis. Moreover, although we corrected our models for a range of clinical and sociodemographic variables, we did not have all information such as clinical risk group, the degree of nerve‐sparing, urinary outcome scores and most importantly baseline SEF, which might have influenced either the treatment choice or the outcome. Additionally, we were not able to identify trends over time, as HRQoL in the PROCAS study was assessed only once for each participant. Other studies indicated that HRQoL of PC survivors appears to be lower during and shortly after treatment, but to improve and stabilize thereafter.[^8^](#cam43197-bib-0008){ref-type="ref"}, [^33^](#cam43197-bib-0033){ref-type="ref"}, [^34^](#cam43197-bib-0034){ref-type="ref"} However, due to the cross‐sectional design of our study, causality between NSRP and better sexual outcomes cannot be established. Finally, information on whether RP was performed open or robotic‐assisted was not assessed in the study, what might also influence the generalizability of our results even though these two techniques yielded similar functional outcomes in short‐term PC survivors as seen in randomized controlled trials.[^35^](#cam43197-bib-0035){ref-type="ref"}

7. CONCLUSION {#cam43197-sec-0015}
=============

In conclusion, NSRP was generally associated with comparable long‐term HRQoL outcomes but higher sexual activity scores when compared to Non‐NSRP. Our results support nerve‐sparing techniques as an option to improve post‐operative sexual but not urinary outcomes after RP in PC survivors.
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